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Breast cancer is the second most pervasive cause of mortalities in the 
world and Tamoxifen is the hormone therapy of choice in pre-
menopausal estrogen receptor positive breast cancer women and 
sometimes in post-menopausal women. The pharmgeonetics factors 
widely affect the pharmacokinetic parameters. Information regarding 
this anti breast cancer drug shows that bio disposition of Tamoxifen 
has not been widely studied in local healthy adult female subjects.  
Disposition kinectics and dosage regimen were investigated in eight 
healthy adult females of a specific age group 35-55 years. Blood 
samples were collected at various intervals after oral administration 
20mg Tamoxifen tablet. Plasma concentrations were determined with 
HPLC. Plasma concentration versus time curve was analyzed with one  
compartment pharmacokinetic model to calculate the kinetic parameters such as Cmax and 
volume of distribution etc. The pharmacokinetic analysis revealed Cmax of 28.11 ± 2.11 
ng/mL at mean Tmax of 7.7 hours.The mean ± SE volume of distribution was 306.6 ± 3.681 
L/kg ,respectively while extrapolated zero time drug concentration of elimination phase 0.037 
± 0.005ng/mL. Mean ± SE rate constant for elimination phase was 0.12 ± 0.002 hr
-1
. Due to 
decrease in Cmax attained after single oral dose, it is recommended that dosing interval of 
Tamoxifen should be decreased as to attain steady state levels for pharmacotherapeutic 
results in breast cancer females. However, 5-10ng/mL change is due to the changes of 
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environment, epigenetic and genetic variation between Pakistan and drug manufacturing 
foreign countries. 
 
KEYWORDS: Pharmacokinetics, Tamoxifen Dosage Regimen, Disposition Kinetics. 
 
INTRODUCTION 
Breast cancer is the second highly important cause of mortalities in the world. Unfortunately 
our health sector is far away from the standard treatment guidelines (Shahbaz et al., 2015) to 
cure such killing diseases. Metastatic breast cancer is more drastic as the main causative 
agent is not known. Although, multiple causes have been known to be involved in the 
metastatic breast cancer, but still chemotherapy is a question to absolutely treat this cancer 
(Shahbaz et al., 2014). 1.3 million Women suffer from breast cancer in United States. 
Similarly 1 out of every 8 women had breast cancer reported in 2014 (Breast Cancer, 2013). 
Not only humans but also animals become victim of breast cancer as shown by the research 
on cow’s breast cancer at Harvard University in 2006. Among the chemotherapeutic anti-
estrogens, tamoxifen is the most essential as being used for 40 years worldwide and for 20 
years in Pakistan. Yet there is no appropriate data for this medicine to support its entire 
kinetics and dynamics in the environment of Pakistan. Contrary to the previous decade when 
cervical cancer was the major cause of death now breast cancer accounts for highest 
morbidity and mortality rate in females (Jemal et al, 2011). The precise number of mortality 
and number of cancer cases in Pakistan are unknown (Hanif et al., 2009). It is for sure to 
research those areas which causes highest human deaths as human life and its quality is the 
focus. 
 
Tamoxifen is on the World Health Organization's List of Essential Medicines (WHO, 2014). 
Tamoxifen was introduced by EstraZeneca of UK for the first time and being frequently 
prescribed as hormonal therapy of estrogen positive breast cancer in the clinics of Pakistan. It 
is far better to use right medicine with right dose at the right stage of the disease to opt 
maximum curative results. The exact kinetic and dynamic mechanism within human is 
necessary for manufacturing drugs against any disease. 
 
It binds to estrogen receptors competitively in tumor cells and other tissue targets, thus 
producing a nuclear complex that decreases DNA production and inhibits estrogen action. It 
is not a steroidal agent with potent antiestrogenic properties which compete with estrogen 
binding sites in breast and metabolized in liver by Cyp 2D6 (cytochrome P450, family 
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2,subfamily D, polypeptide 6), rendering active metabolites of tamoxifen includes N-
desmethyl Tamoxifen, endoxifen and 4 hydroxy Tamoxifen (Fuchs et al., 1996). It binds 
competitively to estrogen receptor in such an intact lock that no space remains for estrogen, 
hence tumor growth decreases. Its half-life is 7-14 hours. A single oral tablet of 20 mg of 
Tamoxifen shows an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) 
observed approximately five hours after dosing. The decline in plasma concentrations of 
Tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 hours (Furr et al., 
1984). 
 
Like other chronic ailment’s treatment, the treatment of breast cancer can be at a better stance 
if there is more patient compliance and less side effects. The Most common side effects 
caused by Tamoxifen are nausea, hot flashes, vaginal dryness loss of sexual desire. It is 
notable that Tamoxifen is not an antagonist all tissues like in breast tissue. It, therefore, has 
agonist effect in bones and ovaries. In addition, it does not has a cardioprotective effect on 
heart and causes thromboembolism and fatty liver. It shows a reduction in libido and 
evidences of decreased cognition have been reported. 
 
Its use comprises of ER positive breast cancer, bipolar disorder (Yildiz et al., 2008), 
infertility (Steiner et al., 2005) and gynaecomastia. It is approved by the FDA for preventing 
breast cancer in woman at highest risk (FDA 2007). Similarly, it is effective in both pre and 
postmenopausal women. In addition to its use as prophylaxis of breast cancer risks, it reduces 
the recurrence after mastectomy. 
 
Genetic variations in Cyp-2D6 enzyme among various people have shown 20% of decrease 
in the pharmacological action of Tamoxifen (schroth et al. 2009). It is a prodrug and its active 
metabolites may only support an antiestrogen therapy as they change by Cyp-3A4 and Cyp-
2D6 (Desta et al., 2004). Genotype, therefore, has an essential implication on the outcomes of 
patients taking Tamoxifen as breast cancer therapy. On Oct 18, 2006 the Subcommittee for 
Clinical Pharmacology recommended relabeling of Tamoxifen to include information about 
this gene in the package insert (DNA Direct, Inc. 2012-2013). There is a huge impact of 
genetic polymorphism on the pharmacokinetics in various people due to the change in 
various enzymes and proteins (Mizuno et al., 2012). 
 
Pakistan imports raw and finished drugs for human and veterinary use. It has been reported 
that genetic make-up in local human & animals and environmental conditions are different 
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than those of their foreign counterparts (Javed et al., 2006). These differences are manifested 
through the variation in pharmacokinetic and bioavailability parameters suggesting that 
pharmacokinetic and bioavailability of these drugs should be investigated in the species and 
environment in which drug is going to be utilized ultimately (Javed et al., 2009a). From these 
studies it may be concluded that biochemical milieu interieur and physiological parameters 
are influenced by environmental and genetic conditions, which ultimately affect the 
disposition kinetic and are likely to affect response to the drugs. Several investigations in 
animal models have shown that biodisposition of certain drugs i.e. sulfonamides and 
antibiotics under indigenous conditions is different from the disposition recorded elsewhere 
(Nawaz et al., 1989; Javed et al., 2009b; Hussain et al., 2014). Therefore, it is necessary that 
an optimal dosage regimen should be based on the pharmacokinetics data determined in the 
local species and environment in which a drug is to be used clinically. 
 
Information regarding this anti breast cancer drug shows that biodisposition of Tamoxifen has 
not been widely studied in local healthy adult female subjects. In view of the stated facts, the 
present project has been planned to investigate pharmacokinetics of Tamoxifen in local 
healthy adult female subjects. Also the eight female volunteers were observed for 4 weeks to 
check any sign or symptom i-e., nausea, vomiting, hot flashes etc. after single oral dose. 
However, this is the first study about Tamoxifen pharmacokinetics in Pakistan to benefit 
Breast cancer patients in our environment. 
 
MATERIAL AND METHOD  
For the study of Pharmacokinetics of Tamoxifen eight female volunteers were considered. 
These volunteers were selected from University or nearby residential area of Faisalabad. 
 
Selection Criteria 
Volunteers of age group 35-65 years were selected after physical examination and clinical 
history to be declared as healthy. All volunteers were informed about the objective of study, 
frequency of sampling and possible side effects of drug and written consent with each 
volunteer was made. 
 
Drug/ Chemicals 
Tamoxifen, 20 mg tablet from ICI Pvt. Ltd., Lahore, Pakistan was taken. 
The following chemicals used in the entire study were of HPLC grade 
 Ammonium acetate(Merck, Germany) 
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 Acetonitrile (Fischer Scientific Limited, UK) 
 Methanol (Fischer Scientific Limited, UK) 
 Deionized water 
 
A single dose of Tamoxifen 20 mg tablet of Nolvadex brand was given orally to each 
volunteer after breakfast. In all experiments, a blood blank sample was collected before drug 
administration. Blood sample of 5ml each was collected from the cubital vein of each 
volunteer either directly with the help of a disposable syringe or through I.V cannula of 20 
gauge needle at 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 24 hours after oral dose. The pH of fresh sample 
of blood was noted in each experiment by a pH meter (Beckman HS, Germany) with a glass 
electrode at 37
0




Tamoxifen concentration in plasma samples was determined using HPLC (Sykam, S-3210) 
analytical method using UV/Vis detector (Sykam, S-3210) (Kashtiaray et al. 2011). 
Pharmacokinetic calculations were done with the computer programme MW/PHARM version 
3.02 by F. Rombout, in cooperation with University Centre for Pharmacy, Department of 
Pharmacology and Therapeutics, University of Gronigen & Medi/Ware, copy right 1987-1991. 
Based on kinetic parameters; optimal dosage regimens of Tamoxifen was calculated in healthy 
adult female subjects (Baggot, 1977).  
 
Statistical analysis 
The mean value and standard error of mean ±SE for each concentration and parameter was 
calculated. Plasma concentration versus time data was subjected to regression analysis following 
one compartment open model for calculations of disposition kinetic parameters. The mean ±SE 
was computed according to the standard statistical method and data was analyzed by least 
square regression/correlation analysis using Microsoft Excel version. 
 
Stock solution was prepared by dissolving 1 mg of the reference standard in 1.0 ml of HPLC-
grade methanol and mixture was diluted to 10 ml with distilled water. This stock solution was 
refrigerated at 3C⁰ for up to one week. Further 1.0mg per ml of the stock solution was diluted 
with distilled water to prepare an additional standard that was 100 nanogram per ml. 
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Calibration standard for the plasma assay was prepared by adding 100 microliter of the 100 
nanogram per ml Tamoxifenstock solution to appropriate volume of drug-free plasma. 
Plasma Tamoxifen calibration standard curve was prepared at concentration of 0.5, 1, 2 and 4 
Nanogram per ml. 
 
The mobile phase was prepared fresh on the day of analysis by combining 70/30 v/v of 
acetonitrile and ammonium acetate (0.05M). For the adjustment of pH ammonium acetate 
was used and was filtered and degased by vacuum before use. A 200μl aliquot of the plasma 
standard was filtered to a propylene 1.5 ml snap-Cap centrifuge tube & 20μl of the working 
acetonitrile was added. The tube was vortexed at high speed for 15 second and centrifuged at 
12000G for 10 min. The clear supernatant was taken and 100 μl was injected for each 
analysis. The Tamoxifen plasma concentrations were determined by regression equation from 
the standard curve of Tamoxifen, Figure 2. 
 
The plasma concentration versus time data was plotted on semilogrithmic graph paper and 
analysed by one compartment open model. The pharmacokinetic parameters calculations 
were computed with the computer programme MW/PHRAM version 3.02 by F. Rombout, a 
MEDI WARE product APO pharmacological analysis in the cooperation with University 
Centre for Pharmacy, Department of Pharmacology and Therapeutics, University of Gronigen 
and Medi/Ware, copy right 1987-1991.  
 
Figure 2: Standard Curve of Tamoxifen 
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RESULTS 
The values of plasma concentrations, disposition kinetic parameters of Tamoxifen in healthy 
adult females are determined which are far from pharmacokinetic parameters of tamoxifen in 
other countries due to epigenetics. 
 
Plasma concentration of the drug 
After oral administration the concentration of Tamoxifen at various time intervals for 
volunteer has been presented in respective figure 4. Mean ± SE (ng/mL) values for these 
results are given in table 1. 
 
 
Figure: 4 Plasma concentration of Tamoxifen on a semilogarithmic scale versus time 
after single oral administration of Tamoxifen 20mg tablet in 8 healthy females. 
Optimal dose 
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The optimal dosage regimens of Tamoxifen based upon the pharmacokinetic parameters were 
calculated in female volunteers. The calculations of priming and maintenance doses of 
Tamoxifen after oral administration were based upon the minimum effective concentration 
(MEC) of Tamoxifen in blood. The minimum effective concentrations of Tamoxifen CP 
(min) 20, 30, 40 ng/ml have been used in the calculations for each time interval. 
 
The oral doses of Tamoxifen in mg/kg body weight for 8, 12 and 24 hour intervals in females 
have been presented in Table 2. Graphically, dose and dosing intervals of Tamoxifen in the 
adult female volunteers have been presented as “dosogram” in Fig 4. The doses of Tamoxifen 
in females at CP (min) 30ng/ml were 10.4, 15.6 and 21mg/kg for 12, 18 and 24 hour dosing 
intervals, respectively. The calculated doses for females at CP (min) 20ng/ml, were 4, 6 and 8 
mg/kg for 12, 18and 24 hour dosing intervals.  
 




Figure 5 Dosage Regimen For Therapeutic CP
o
 Levels At Particular Dosage Intervals 
Determined After Single Dose of Tamoxifen 20mg tablet.  
Pharmacokinetics 
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The log plasma drug concentration versus time profile of Tamoxifen showed a monophasic 
curve, so the kinetic parameters were best fitted by one compartment model method for 
Tamoxifen. However, a decision about two or three compartment model seems to depend on 
the frequency of blood sampling during the initial phase of experiments. For the current 
experiment data one compartment model best fits to the situation. The kinetics parameters for 
Tamoxifen were calculated according to the method (Baggot, 1977).  
 
Volume of Distribution (Vd) 
Mean value of volume of distribution (Vd) of Tamoxifen was 306.6 L/kg in the local female 
population after single oral administration of 20mg  tablet which was greater than 50-60 L/kg 
after oral dose of 20 mg in females of breast cancer  ( Martindale 1989).  
 
Species Difference 
A comparison of different pharmacokinetics parameter of various drugs in different species 
of animals verified considerable deviation when compared with the literature values ( Nawaz 
and Khan , 1979; Nawaz, 1980; Khan et al., 1980; Nawaz, 1982; Shah and Nawaz, 1986; 
Javed et al., 1984; Ghaffar et al., 1996; Muhammad, 1997 and Javed et al., 2009).Not only 
species but we may observe this change in various age groups. As the value obtained of 




The most common cause of ineffectiveness of Tamoxifen treatment is the inadequate tissue 
concentration (Kiss et al., 1976). The inhibition of estrogen by the Tamoxifen varies not only 
among the species but also among the population within the same species resulting in a very 
wide range of CP
o
 (min) or minimum effective concentration (MEC) against the hormone. 
 
Table: 2 Mean ± SE pharmacokinetic parameters of Tamoxifen Following Oral 
Administration of 20mg in 8 Adult Healthy Female Subjects By One Compartment 
Model 
Subject No. 
Cmax β Vd B 
(ng/mL) (hr
-1
) (l/kg) - 
1 39.74 0.13 311.0 0.03 
2 29.55 0.13 306.6 0.03 
3 23.71 0.13 311.0 0.06 
4 23.83 0.13 307.9 0.03 
5 23.39 0.12 314.8 0.03 
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6 30.23 0.13 306.3 0.03 
7 24.22 0.13 311.1 0.03 
8 30.22 0.13 302.4 0.03 
Mean 28.11 0.12 306.6 0.037 
±SE 2.811 0.002 3.681 .0..0 
 
 
Figure: 7 Chromatogram of 30.5 ng/ml Tamoxifen in the Plasma of Female Volunteers. 
 
 
Figure: 8. Diagrammatic representation of dosage scheme for the breast cancer females 
patients of Pakistan under same environmental conditions to achieve therapeutic levels 
of Tamoxifen. 
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Figure: 9 Healthy female volunteers after administration of single dose of tamoxifen 
20mg and providing blood samples at regular designed intervals. 
 
DISCUSSION 
Pharmacokinetics of Tamoxifen (Nolvadex) of Tamoxifen was investigated following an oral 
dose of 20 mg tablet in eight healthy female volunteers. Plasma samples were collected at 
different time intervals following drug administration, and analyzed for Tamoxifen 
concentration by HPLC method. The minimum effective concentration of Tamoxifen is 30 
ng/ml, that is 40ng/mL in another study (Santana et al., 2008). The minimum effective 
concentration of the Tamoxifen in plasma was persistent during the eight hours (0.05-8.0 
hours) that will assure its pharmacotherapeutic action. 
 
Cmax is defined as the maximum concentration of drug achieved in the plasma. The peak 
plasma concentration is the factor which depends on both the rate of drug absorption and 
extent of drug absorption in the plasma. If less time is required for the drug absorption then 
maximum drug concentration achieved very rapidly. The maximum concentration of single 
dose of Tamoxifen 20 mg after oral administration in the female volunteers with mean ± S.E 
was 28.11 ± 2.11ng/ml. Cmax was achieved at 2.07 hours under the range of 31-33.4 ng/ml. 
However following singe oral dose of tamoxifen 20mg tablet the maximum plasma 
concentration achieved was 40ng/mL(Santana et al., 2008), 141ng/L in adults and 209ng/L in 
pediatrics (Mahra, 2005), 147ng/mL (Aman et al., 1994), 42 ng/mL (Adam et al., 1980) and 
17.8ng/mL(Kashtiaray et al.,2011). Tmax of the present study calculated with ranged 6.05- 7.7 
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hours with mean ± S.E 7.717 ± 0.22 hours and this time increases as its 99% protein boind 
(Ferner et al., 1990).  
 
The absorption rate constant was under the ranged from 0.132-0.148 of with mean ± S.E was 
0.134 ± 0.17hr
-1
in the present study. The value of the distribution phase constant of 
Tamoxifen 20 mg after oral administration with mean ± S.E was 0.120 ± 0.09 hr
-1   
under the 
ranged of 0.04- 0.125 hr
-1
. The extrapolated zero time drug concentration of distribution 
phase of present study ranged from 0.07-0.19 µg/ml with mean ± S.E was 0.14 ± 0.02 µg/ml 
and distribution half-life of 5.26 ± 0.05Hrs.  
 
The overall elimination rate constant ranged from 0.132-0.135 hr
-1
of with mean ± S.E was 
0.129 ± 0.002hr
-1
 and Extrapolated zero time drug concentration of elimination phase (Β, 
µg/ml) is 0.129 ± 0.002hr
-1
. Apparent volume of distribution was (mean ± S.E) 306.6 ± 3.68 
L/Kg. This Vd parameter is very important for many other kinetics parameters; if volume of 
distribution is altered it may responsible for the change of other parameters. Volume of 
distribution depends on many biological factors. Vd range is vast 201-1071 L (Mahra 2005), 
50-60L/Kg in another study (Ernst et al., 1991) thus if Vd increases the half-life of a drug 
also increases and vice versa. 
 
Rate constant for elimination ranged between 0.132-0.135 hr
-1
. K12 is the first order transfer 
rate constant for distribution between the central compartment and peripheral compartment 
ranged between 1.29 to 1.49 Hr
-1




Optimal dosage regimens and hence the MEC of Tamoxifen 30ng/ml has been used in the 
calculations. Based on the different pharmacokinetic parameters of the present study the 
primary and maintenance dose 21 mg have been recommended with the dosing interval of 24 
hours in local population. Following this dosage regime the population of Pakistan will get 
the optimum therapeutic levels of 30 ng/mL in the blood. Thus our current study supports the 
manufacturer’s recommendation to some extent as enzymatic effects are still unknown 
(Shahbaz. 2016). However to get more levels of tamoxifen in blood like at 40-45 ng/mL as 
proposed in some studies, a tablet of more milligram should be prepared accordingly to fit the 
dosage in our population. It is concluded that the current dosage form of tamoxifen is not so 
far from the standard criterion as proposed in this research however small concentration 
change bring drastic changes in the course of cancer treatment. Similarly a new tablet with 
different dosage regimen should be designed to overcome the lower blood concentration 
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levels in the Pakistan’s population. So, a dosage interval after 18 hours will provide best 
therapeutic concentration to the patients. It is because level of CYP2D6 varies in the various 
individuals of even same geographical region. Lower the Cyp2d6 levels lower the therapeutic 
metabolite of tamoxifen in the body. 
 
CONCLUSION 
On the basis of results it is concluded that epigenetic factor and level of enzyme should be 
checked while advising its dose. However current study proposes 21mg of tamoxifen dose 
every 24 hours which is very close to manufacturer’s recommendations whereas when the 
therapeutic levels of 35-40ng/mL of tamoxifen are required according to some researches, 
dosage interval should be decreased. High volume of distribution is due to healthy condition 
of the female volunteers and shows well absorption of drug in the tissues. The value of Cmax 
also reveals good absorption of the drug in Pakistani woman and concept of pharmgeonetics 
is observed (Shahbaz. 2016). 
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